BACKGROUND: Camptocormia is defined as an abnormal flexion of the trunk that appears when standing or walking and disappears in the supine position. The origin of the disorder is unknown, but it is usually attributed either to a primary or a secondary paravertebral muscle myopathy or a motor neurone disorder. Camptocormia is also observed in a minority of patients with parkinsonism. OBJECTIVE: To characterise the clinical and electrophysiological features of camptocormia and parkinsonian symptoms in patients with Parkinson's disease and camptocormia compared with patients with Parkinson's disease without camptocormia. METHODS: Patients with parkinsonism and camptocormia (excluding patients with multiple system atrophy) prospectively underwent a multidisciplinary clinical (neurological, neuropsychological, psychological, rheumatological) and neurophysiological (electromyogram, ocular movement recording) examination and were compared with age-matched patients with Parkinson's disease without camptocormia. RESULTS: The camptocormia developed after 8.5 (SD 5.3) years of parkinsonism, responded poorly to levodopa treatment (20%) and displayed features consistent with axial dystonia. Patients with camptocormia were characterised by prominent levodopa-unresponsive axial symptoms (ie, axial rigidity, gait disorder and postural instability), along with a tendency for greater error in the antisaccade paradigm. CONCLUSION: We suggest that (1) the salient features of parkinsonism observed in patients with camptocormia are likely to represent a specific form of Parkinson's disease and camptocormia is an axial dystonia and (2) both camptocormia and parkinsonism in these patients might result from additional, non-dopaminergic neuronal dysfunction in the basal ganglia.
BACKGROUND: Camptocormia is defined as an abnormal flexion of the trunk that appears when standing or walking and disappears in the supine position. The origin of the disorder is unknown, but it is usually attributed either to a primary or a secondary paravertebral muscle myopathy or a motor neurone disorder. Camptocormia is also observed in a minority of patients with parkinsonism. OBJECTIVE: To characterise the clinical and electrophysiological features of camptocormia and parkinsonian symptoms in patients with Parkinson's disease and camptocormia compared with patients with Parkinson's disease without camptocormia. METHODS:Patients with parkinsonism and camptocormia (excluding patients with multiple system atrophy) prospectively underwent a multidisciplinary clinical (neurological, neuropsychological, psychological, rheumatological) and neurophysiological (electromyogram, ocular movement recording) examination and were compared with age-matched patients with Parkinson's disease without camptocormia. RESULTS: The camptocormia developed after 8.5 (SD 5.3) years of parkinsonism, responded poorly to levodopa treatment (20%) and displayed features consistent with axial dystonia. Patients with camptocormia were characterised by prominent levodopa-unresponsive axial symptoms (ie, axial rigidity, gait disorder and postural instability), along with a tendency for greater error in the antisaccade paradigm. CONCLUSION: We suggest that (1) the salient features of parkinsonism observed in patients with camptocormia are likely to represent a specific form of Parkinson's disease and camptocormia is an axial dystonia and (2) both camptocormia and parkinsonism in these patients might result from additional, non-dopaminergic neuronal dysfunction in the basal ganglia.
Authors: T Umapathi; V Chaudhry; D Cornblath; D Drachman; J Griffin; R Kuncl Journal: J Neurol Neurosurg Psychiatry Date: 2002-07 Impact factor: 10.154
Authors: Irene Litvan; Kailash P Bhatia; David J Burn; Christopher G Goetz; Anthony E Lang; Ian McKeith; Niall Quinn; Kapil D Sethi; Cliff Shults; Gregor K Wenning Journal: Mov Disord Date: 2003-05 Impact factor: 10.338
Authors: Wolf-Rüdiger Schäbitz; Katharina Glatz; Christian Schuhan; Clemens Sommer; Christian Berger; Markus Schwaninger; Marius Hartmann; Hans Hilmar Goebel; Hans-Michael Meinck Journal: Mov Disord Date: 2003-04 Impact factor: 10.338
Authors: S Rivaud-Péchoux; M Vidailhet; G Gallouedec; I Litvan; B Gaymard; C Pierrot-Deseilligny Journal: Neurology Date: 2000-03-14 Impact factor: 9.910
Authors: Alfonso Fasano; Christian Geroin; Alfredo Berardelli; Bastiaan R Bloem; Alberto J Espay; Mark Hallett; Anthony E Lang; Michele Tinazzi Journal: Parkinsonism Relat Disord Date: 2018-05-08 Impact factor: 4.891
Authors: Tim Hagenacker; Marcus Gerwig; Thomas Gasser; Dorothea Miller; Oliver Kastrup; Daniel Jokisch; Ulrich Sure; Markus Frings Journal: J Neurol Date: 2013-03-13 Impact factor: 4.849